Senseonics Holdings downgraded by SVB Leerink with a new price target
$SENS
Industrial Machinery/Components
Industrials
SVB Leerink downgraded Senseonics Holdings from Outperform to Market Perform and set a new price target of $3.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2023 | $0.50 | Underperform | Jefferies |
| 8/19/2021 | $6.00 | Buy | HC Wainwright & Co. |
Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia Patient base increased 56% in 2024 over 2023 to approximately 6,000 global patients GERMANTOWN, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the fourth quarter ended December 31, 2024. Recent Highlights & Accomplishments: Eversense® 365 approved and launched in the U.S. during 2024 as an integrated contin
Senseonics and Ascensia integrate software between SweetSpot and Eversense 365, the world's first and only One Year CGM system SweetSpot partners with endocrinology practices to provide virtual CGM monitoring and enhanced patient care GERMANTOWN, Md. and PARSIPPANY, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) and Ascensia Diabetes Care announce the software integration of SweetSpot™ with the Eversense® 365 Continuous Glucose Monitoring (CGM) System in the U.S. This software integration provides endocrinology practices that partner with SweetSpot the ability to continue to improve patient care by seamlessly and regularly reviewing data from patients u
GERMANTOWN, Md., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming TD Cowen 45th Annual Health Care Conference, being held in Boston, MA. TD Cowen 45th Annual Health Care Conference Format: Corporate overview and one-on-one meetingsDate: Tuesday, March 4, 2025Time: 3:10 pm ETWebcast: Click here Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company's website at www.senseoni
10-K - Senseonics Holdings, Inc. (0001616543) (Filer)
8-K - Senseonics Holdings, Inc. (0001616543) (Filer)
8-K - Senseonics Holdings, Inc. (0001616543) (Filer)
Jefferies initiated coverage of Senseonics with a rating of Underperform and set a new price target of $0.50
HC Wainwright & Co. initiated coverage of Senseonics Holdings with a rating of Buy and set a new price target of $6.00
SVB Leerink downgraded Senseonics Holdings from Outperform to Market Perform and set a new price target of $3.00
Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia Patient base increased 56% in 2024 over 2023 to approximately 6,000 global patients GERMANTOWN, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the fourth quarter ended December 31, 2024. Recent Highlights & Accomplishments: Eversense® 365 approved and launched in the U.S. during 2024 as an integrated contin
GERMANTOWN, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2024 financial results after market close on Monday, March 3, 2025. Management will hold a conference call to review the Company's fourth quarter and full year 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at
GERMANTOWN, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights & Accomplishments: Eversense® 365 approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetesCommercialization, now in process, driven by Senseonics' global commercial partner, Ascensia Diabetes Care, a subsidiary of PHC Holdings CorporationMercy health system inserted the
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)
4/A - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)